专利检索 ap:"Erwin R. BOGHAERT" 第 1 页

1.

发明授权
Anti-5T4 antibodies and uses thereof 有权
标题翻译：抗-5T4抗体及其用途

公开(公告)号：US08044178B2

公开(公告)日：2011-10-25

申请号：US11684329

申请日：2007-03-09

申请人： Erwin R. Boghaert , Nitin K. Damle , Philip Ross Hamann , Kiran Khandke , Arthur Kunz , Kimberly A. Marquette , Lioudmila Tchistiakova , Davinder Gill , Kodangattil Sreekumar

发明人： Erwin R. Boghaert , Nitin K. Damle , Philip Ross Hamann , Kiran Khandke , Arthur Kunz , Kimberly A. Marquette , Lioudmila Tchistiakova , Davinder Gill , Kodangattil Sreekumar

IPC分类号： C07K16/00 , C07K17/00 , C07K17/14 , C12P21/08 , A61K39/395 , A61K39/00

CPC分类号： C07K16/28 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K14/82 , C07K16/30 , C07K16/32 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/77 , C07K2317/92

摘要： Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.

摘要翻译： 抗5T4抗体，抗5T4抗体/药物偶联物，以及制备和使用该抗体的方法。

2.

发明申请
BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same 审中-公开
标题翻译： BCL-XL抑制剂及其抗体药物结合物

公开(公告)号：US20160158377A1

公开(公告)日：2016-06-09

申请号：US14963510

申请日：2015-12-09

申请人： Scott L. Ackler , Nathan B. Bennett , Erwin R. Boghaert , Steve C. Cullen , George Doherty , Robin R. Frey , Anthony R. Haight , Andrew S. Judd , Aaron R. Kunzer , Xiaoqiang Shen , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Xilu Wang , Dennie S. Welch , Michael D. Wendt

发明人： Scott L. Ackler , Nathan B. Bennett , Erwin R. Boghaert , Steve C. Cullen , George Doherty , Robin R. Frey , Anthony R. Haight , Andrew S. Judd , Aaron R. Kunzer , Xiaoqiang Shen , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Xilu Wang , Dennie S. Welch , Michael D. Wendt

IPC分类号： A61K47/48 , C07K16/18 , C07D513/04 , C07D417/14 , C07D487/04

CPC分类号： C07K16/18 , A61K47/6803 , C07D417/14 , C07D487/04 , C07D513/04 , C07K2317/73

摘要： Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.

摘要翻译： 本文公开了包含小分子Bcl-xL抑制剂的小分子Bcl-xL抑制剂和抗体药物偶联物（ADC）。本公开的Bcl-xL抑制剂和ADC尤其可用于抑制抗凋亡Bcl-xL蛋白作为治疗涉及失调性凋亡途径的疾病的治疗方法。

3.

发明授权
Therapeutic DLL4 binding proteins 有权
标题翻译：治疗性DLL4结合蛋白

公开(公告)号：US08623358B2

公开(公告)日：2014-01-07

申请号：US12870276

申请日：2010-08-27

申请人： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe

发明人： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe

IPC分类号： A61K39/395

CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/18 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94

摘要： Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

摘要翻译： 描述了改进的DLL4结合蛋白，包括抗体，CDR-移植抗体，人抗体和DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成和/或其它血管发生依赖性疾病，例如眼新生血管形成或以异常DLL4表达或活性为特征的血管发生非依赖性疾病，例如自身免疫包括多发性硬化的疾病。

4.

发明申请
HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATES 审中-公开
标题翻译：抗人抗原5T4抗体和抗-5T4 /卡培他滨联合

公开(公告)号：US20100173382A1

公开(公告)日：2010-07-08

申请号：US12580702

申请日：2009-10-16

申请人： Erwin R. Boghaert , Nitin K. Damle , Davinder S. Gill , Kimberly A. Marquette , Lioudmila Tchistiakova , Philip Ross Hamann , Arthur Kunz

发明人： Erwin R. Boghaert , Nitin K. Damle , Davinder S. Gill , Kimberly A. Marquette , Lioudmila Tchistiakova , Philip Ross Hamann , Arthur Kunz

IPC分类号： C12N9/96 , C07K16/00

CPC分类号： C07K16/3046 , A61K47/60 , A61K47/6809 , A61K47/6851 , A61K2039/505 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K2317/24 , C07K2317/56 , C07K2317/567 , C07K2317/622 , C07K2317/92

摘要： Chimeric and humanized anti-5T4 antibodies and antibody/drug conjugates and methods for preparing and using the same.

摘要翻译： 嵌合和人源化抗5T4抗体和抗体/药物共轭物及其制备和使用方法。

5.

发明申请
ANTI-5T4 ANTIBODIES AND USES THEREOF 有权
标题翻译： ANTI-5T4抗体及其用途

公开(公告)号：US20120064600A1

公开(公告)日：2012-03-15

申请号：US13208162

申请日：2011-08-11

申请人： Erwin R. BOGHAERT , Nitin K. Damle , Philip Ross Hamann , Kiran Khandke , Arthur Kunz , Kimberly A. Marquette , Lioudmila Tchistiakova , Davinder Gill , Kodangattil R. Sreekumar

发明人： Erwin R. BOGHAERT , Nitin K. Damle , Philip Ross Hamann , Kiran Khandke , Arthur Kunz , Kimberly A. Marquette , Lioudmila Tchistiakova , Davinder Gill , Kodangattil R. Sreekumar

IPC分类号： C07K16/30 , A61P31/00 , A61P37/02 , A61P35/00 , C07K19/00 , C12N9/96

CPC分类号： C07K16/28 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K14/82 , C07K16/30 , C07K16/32 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/77 , C07K2317/92

摘要： Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.

摘要翻译： 抗5T4抗体，抗5T4抗体/药物偶联物，以及制备和使用该抗体的方法。

6.

发明申请
THERAPEUTIC DLL4 BINDING PROTEINS 有权
标题翻译：治疗DLL4结合蛋白

公开(公告)号：US20110117079A1

公开(公告)日：2011-05-19

申请号：US12870276

申请日：2010-08-27

申请人： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe

发明人： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe

IPC分类号： A61K39/395 , C07K16/18 , C12N9/96 , C07H21/04 , C12N15/63 , C12N1/21 , C12N5/10 , C12N1/19 , C12P21/00 , A61P35/00 , A61P13/08 , A61P9/10 , A61P17/02 , A61P35/04

CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/18 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94

摘要： Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

摘要翻译： 描述了改进的DLL4结合蛋白，包括抗体，CDR-移植抗体，人抗体和DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成和/或其它血管发生依赖性疾病，例如眼新生血管形成或以异常DLL4表达或活性为特征的血管发生非依赖性疾病，例如自身免疫包括多发性硬化的疾病。